Picoplatin: Final Phase III data

Final data from the open-label, international Phase III SPEAR trial in 401 patients showed that IV picoplatin once every 3 weeks plus best supportive care (BSC) had a median OS of 20.6 weeks

Read the full 336 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE